Immunic (IMUX)
(Delayed Data from NSDQ)
$1.22 USD
-0.04 (-3.18%)
Updated Apr 26, 2024 04:00 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Cash flow Statements
Fiscal Year End for Immunic, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -93.61 | -120.41 | -92.95 | -44.02 | -34.93 |
Depreciation/Amortization & Depletion | 0.11 | 33.05 | 0.09 | 0.04 | 0.05 |
Net Change from Assets/Liabilities | 15.05 | 9.53 | -9.28 | -2.37 | -1.36 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.63 | 12.69 | 18.91 | 0.22 | 7.70 |
Net Cash From Operating Activities | -70.83 | -65.14 | -83.23 | -46.12 | -28.55 |
Property & Equipment | -0.33 | -0.11 | -0.07 | -0.15 | 2.46 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 8.15 |
Investments | 9.80 | -9.63 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | -0.08 |
Net Cash from Investing Activities | 9.46 | -9.74 | -0.07 | -0.15 | 10.54 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.03 | 95.76 | 42.84 | 144.43 | 35.17 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | -0.27 |
Net Cash from Financing Activities | 1.03 | 95.76 | 42.84 | 144.43 | 34.90 |
Effect of Exchange Rate Changes | 0.26 | -0.99 | -0.13 | -0.08 | -0.59 |
Net Change In Cash & Equivalents | -60.07 | 19.88 | -40.59 | 98.08 | 16.30 |
Cash at Beginning of Period | 106.75 | 86.86 | 127.45 | 29.37 | 13.07 |
Cash at End of Period | 46.67 | 106.75 | 86.86 | 127.45 | 29.37 |
Diluted Net EPS | -2.11 | -3.78 | -3.93 | -2.81 | -4.52 |
Fiscal Year End for Immunic, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -93.61 | -72.04 | -49.27 | -25.27 |
Depreciation/Amortization & Depletion | NA | 0.11 | 0.09 | 0.05 | 0.03 |
Net Change from Assets/Liabilities | NA | 15.05 | 8.98 | 5.29 | 3.23 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 7.63 | 6.18 | 4.44 | 2.50 |
Net Cash From Operating Activities | NA | -70.83 | -56.80 | -39.49 | -19.51 |
Property & Equipment | NA | -0.33 | -0.17 | -0.13 | -0.10 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 9.80 | 9.80 | 9.80 | 5.44 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 9.46 | 9.63 | 9.67 | 5.34 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 1.03 | 0.43 | 0.05 | 0.05 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.10 | 0.00 |
Net Cash from Financing Activities | NA | 1.03 | 0.43 | 0.15 | 0.05 |
Effect of Exchange Rate Changes | NA | 0.26 | -0.31 | 0.22 | 0.14 |
Net Change In Cash & Equivalents | NA | -60.07 | -47.06 | -29.45 | -13.98 |
Cash at Beginning of Period | NA | 106.75 | 106.75 | 106.75 | 106.75 |
Cash at End of Period | NA | 46.67 | 59.69 | 77.29 | 92.76 |
Diluted Net EPS | NA | -0.48 | -0.51 | -0.54 | -0.58 |